Example: biology
AUSTRALIAN PRODUCT INFORMATION – COMIRNATY …
COMIRNATY (BNT162b2[mRNA]) COVID-19 Vaccine has provisional approval for the indication below: Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV- 2, in individuals 16 years of age and older. The use of this vaccine should be in accordance with official recommendations.
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
COMIRNATY™ COVID-19 VACCINE
www.tga.gov.auDo not receive this vaccine if you are allergic to any of these ingredients. What COMIRNATY looks like COMIRNATY is a white to off-white suspension provided in a multidose clear glass vial. After dilution, each vial contains 6 doses of vaccine. AUST R 346290. Who distributes COMIRNATY Pfizer Australia Pty Ltd Sydney NSW www.pfizer.com.au
Australian public assessment report for BNT162b2 (mRNA)
www.tga.gov.auThe RNA is encapsulated in lipid nanoparticles (LNPs), which enables entry into host cells, expression of the S protein, and elicitation of both antibody and cellular immune responses. The vaccine is supplied as a white to off white sterile frozen liquid, packaged in a multi dose clear glass 2 mL vial with a rubber stopper,
AUSTRALIAN PRODUCT INFORMATION (ChAdOx1-S) …
www.tga.gov.auAUSTRALIAN PRODUCT INFORMATION COVID-19 Vaccine AstraZeneca (ChAdOx1-S) solution for injection . 1 NAME OF THE MEDICINE . ChAdOx1-S (provisional ABN) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION . Each multi-dose vial contains 5x10. 11. viral particles (vp) of (ChAdOx1-S . a, b) in 5 mL. One dose (0.5 mL) contains 5x10. 10. vp of …
Guideline for the labelling of medicines
www.tga.gov.auGuideline for the labelling medicines of istorical consultation document Draft - Version 1.0, August 2014
Australian public assessment report for Linagliptin
www.tga.gov.au• An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission.
Australian Public Assessment Report for Silodosin
www.tga.gov.auAustralian Public Assessment Report for Silodosin Proprietary Product Name: Urorec ... • To report a problem with a medicine or medical device, please see the information on ... //www.tga.gov.au>. About AusPARs • An Australian Public Assessment Re port (AusPAR) provides information about the evaluation of a prescription medicine and the ...
Guidance 18: Impurities in drug substances and …
www.tga.gov.auTherapeutic Goods Administration Guidance 18: Impurities in drug substances and drug products V1.0 August 2013 Page 3 of 13 Version history Version Description of change Author Effective date
Explanatory notes for pharmaceutical manufacturers on the ...
www.tga.gov.auPE 008-4 3 of 8 1 January 2011 4. SCOPE These Explanatory Notes apply to the preparation and content of the Site Master File. Manufacturers should refer to regional / …
The use of GMDN codes for IVD medical devices in Australia
www.tga.gov.auGlobal Medical Device Nomenclature (GMDN) The GMDN is an international nomenclature system used by regional or national regulatory bodies to consistently describe medical devices: 1 • consistent assessment of devices before they are approved for supply . GMDN codes are used to
COVID-19 rapid antigen self-tests
www.tga.gov.auCOVID-19 rapid antigen self-tests. This guidance refe rs to COVID -19 (caused by SARS-CoV-2) only and does not include self-tests to detect other types of coronavirus , or COVID_19 rapid antibody tests . COVID-19 rapid antigen self-tests are tests that allow individuals to collect a specimen, conduct a test and interpret the results by themselves.
Related documents
PRODUCT MONOGRAPH PFIZER-BIONTECH COVID-19 …
pdf.hres.caPfizer-BioNTech COVID-19 Vaccine [COVID-19 mRNA Vaccine] Product Monograph Page 8 of 28 Record the date and time of dilution on the Pfizer-BioNTech COVID-19 Vaccine vial label. Store between 2°C to 25°C (35°F to 77°F). Discard any unused vaccine 6 hours after dilution.
COVID-19 mRNA Vaccine COMIRNATY® Supplier: Pfizer ...
www.bccdc.caBiologicals and Guidance for Receiving and Handling the Pfizer-BioNTech COVID-19 mRNA Vaccine (including dry ice procedures) . B The date printed on the vial and carton is the date of manufacture. When stored at -90°C to -60°C, the vaccine may be used for up to 6 months from the date of manufacture.
Pfizer-BioNTech COVID-19 Vaccine: 12 Years of Age and ...
www.cdc.govAdminister an additional Pfizer-BioNTech dose at least 28 days after the initial 2-dose primary series.* A primary series started with Pfizer-BioNTech COVID-19 Vaccine should be completed with this product. A booster dose, at least 6 calendar months after the last dose of a COVID-19 mRNA primary series† (i.e., after the 2nd dose
COVID-19 VACCINE STORAGE REQUIREMENTS - AHA
www.aha.orgCOVID-19 VACCINE STORAGE REQUIREMENTS PRIOR TO VIAL USE: • Prior to thawing, store in an ultra-cold freezer between -80°C to -60°C • Once thawed, the vial can be stored undiluted in two ways: – Up to 5 days in a refrigerator – No more than 30 minutes at room temperature Once Vial is First Used: